Skip to content
Open access

Emergency treatment delay and underdosing are associated with poor outcome in non‐convulsive status epilepticus

Jul 2026 · Epilepsia · Vol 67, pp. e163 - e168 · 0 citations · 22 references
Medicine

TL;DR

Early EEG‐based recognition and rapid, adequately dosed ASM treatment as key targets in ED‐NCSE management support early EEG‐based recognition and rapid, adequately dosed ASM treatment as key targets in ED‐NCSE management.

Abstract

Nonconvulsive status epilepticus (NCSE) is difficult to recognize in the emergency department (ED), where onset is often unknown and treatment may be delayed. To what extent treatment timing and dose adequacy are associated with outcome in NCSE remains debated. In this single‐center electroencephalography (EEG)–based study, adults with NCSE diagnosed in the ED were included. Timing was measured using ED arrival as a temporal anchor. Outcomes were failure to return to baseline at discharge and in‐hospital mortality. Among 74 patients (mean age 66.8), 38 (51.4%) failed to return to baseline and 14 (18.9%) died. ED benzodiazepines (BDZs) were administered in 43 patients (58.1%) and anti‐seizure medications (ASMs) in 71 (95.9%). Median times to BDZ and ASM administration were 184 and 223 min, respectively. After adjustment for Status Epilepticus Severity Score (STESS), potentially fatal etiology, and premorbid modified Rankin Scale score, time to ASM (odds ratio [OR]: 1.11 per hour; 95% confidence interval [CI]: 1.01–1.22; p = .037) and ASM underdosing (OR: 3.43; 95% CI: 1.10–10.68; p = .034) were independently associated with failure to return to baseline, with time to BDZ showing a non‐significant trend. BDZ underdosing was not associated with functional outcome, and no treatment variable was associated with mortality. These findings support early EEG‐based recognition and rapid, adequately dosed ASM treatment as key targets in ED‐NCSE management.

Read PDF

Similar papers

Aug 2026

Time over drug in pediatric status epilepticus: A prospective observational study.

Treatment timing, rather than drug selection, was the principal determinant of seizure cessation, emphasizing the importance of rapid escalation of therapy in pediatric refractory CSE.

Michael Nabil Halim, Rasha Hussein Aly Hussein, O. El-Rashidy et al. · 0 citations
Review Open access Aug 2026

Emergent EEG in Status Epilepticus: Off-Hours Delays Limit Clinical Utility.

EEG is essential for diagnosing NCSE and comatose SE and for assessing treatment response in all SE types and for assessing treatment response in all SE types, but marked delays, particularly during off-hours, limit its clinical utility.

Teemu Pöytäkangas, P. Basnyat, J. Saarinen et al. · 0 citations
Open access Sep 2026

Therapeutic coma in non-convulsive status epilepticus is associated with increased complications and mortality: a retrospective cohort study

While therapeutic coma is an established escalation strategy in generalized convulsive status epilepticus, evidence for benefit in non-convulsive status epilepticus (NCSE) is limited and treatment-related complications may affect outcome. We performed a retrospective cohort study of patients with NCSE treated at a tert...

Eyad Altarsha, Norma J. Diel, M. Braun et al. · 0 citations
Open access Aug 2026

Pediatric developmental epileptic encephalopathies treated with cenobamate: Real-world outcomes across etiologies, syndromes, and seizure types.

CNB was associated with sustained effectiveness and acceptable tolerability across pediatric DEEs and slow weight-based titration and proactive simplification of sodium channel blockers and clobazam may optimize benefit-risk.

Á. Aledo-Serrano, Adrián Valls-Carbó, E. González-Alguacil et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.